Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Price, Quote, News and Overview

NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD

1.22  +0.03 (+2.52%)

MRKR Quote, Performance and Key Statistics

MARKER THERAPEUTICS INC

NASDAQ:MRKR (5/1/2025, 9:48:06 AM)

1.22

+0.03 (+2.52%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.99
52 Week Low0.95
Market Cap13.07M
Shares10.71M
Float9.65M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO11-08 2016-11-08


MRKR short term performance overview.The bars show the price performance of MRKR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

MRKR long term performance overview.The bars show the price performance of MRKR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 -60

The current stock price of MRKR is 1.22 USD. In the past month the price increased by 4.39%. In the past year, price decreased by -71.8%.

MARKER THERAPEUTICS INC / MRKR Daily stock chart

MRKR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.64 338.58B
AMGN AMGEN INC 14.36 152.97B
GILD GILEAD SCIENCES INC 13.4 129.26B
VRTX VERTEX PHARMACEUTICALS INC 1727.88 128.82B
REGN REGENERON PHARMACEUTICALS 13.2 63.95B
ARGX ARGENX SE - ADR 333.81 38.73B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.84B
ONC BEIGENE LTD-ADR N/A 27.70B
BNTX BIONTECH SE-ADR N/A 24.07B
NTRA NATERA INC N/A 20.35B
BIIB BIOGEN INC 7.38 17.80B
SMMT SUMMIT THERAPEUTICS INC N/A 17.59B

About MRKR

Company Profile

MRKR logo image Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Company Info

MARKER THERAPEUTICS INC

2450 Holcombe Blvd, Suite Bcm-A, Ms: Bcm251

Houston TEXAS 77027 US

CEO: Peter Hoang

Employees: 8

Company Website: https://markertherapeutics.com/

Investor Relations: https://www.markertherapeutics.com/investors/

Phone: 17134006400

MARKER THERAPEUTICS INC / MRKR FAQ

What is the stock price of MARKER THERAPEUTICS INC today?

The current stock price of MRKR is 1.22 USD. The price increased by 2.52% in the last trading session.


What is the ticker symbol for MARKER THERAPEUTICS INC stock?

The exchange symbol of MARKER THERAPEUTICS INC is MRKR and it is listed on the Nasdaq exchange.


On which exchange is MRKR stock listed?

MRKR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MARKER THERAPEUTICS INC stock?

10 analysts have analysed MRKR and the average price target is 11.09 USD. This implies a price increase of 809.22% is expected in the next year compared to the current price of 1.22. Check the MARKER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MARKER THERAPEUTICS INC worth?

MARKER THERAPEUTICS INC (MRKR) has a market capitalization of 13.07M USD. This makes MRKR a Nano Cap stock.


How many employees does MARKER THERAPEUTICS INC have?

MARKER THERAPEUTICS INC (MRKR) currently has 8 employees.


What are the support and resistance levels for MARKER THERAPEUTICS INC (MRKR) stock?

MARKER THERAPEUTICS INC (MRKR) has a resistance level at 1.25. Check the full technical report for a detailed analysis of MRKR support and resistance levels.


Is MARKER THERAPEUTICS INC (MRKR) expected to grow?

The Revenue of MARKER THERAPEUTICS INC (MRKR) is expected to decline by -61.26% in the next year. Check the estimates tab for more information on the MRKR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MARKER THERAPEUTICS INC (MRKR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MARKER THERAPEUTICS INC (MRKR) stock pay dividends?

MRKR does not pay a dividend.


When does MARKER THERAPEUTICS INC (MRKR) report earnings?

MARKER THERAPEUTICS INC (MRKR) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of MARKER THERAPEUTICS INC (MRKR)?

MARKER THERAPEUTICS INC (MRKR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).


What is the Short Interest ratio of MARKER THERAPEUTICS INC (MRKR) stock?

The outstanding short interest for MARKER THERAPEUTICS INC (MRKR) is 2.04% of its float. Check the ownership tab for more information on the MRKR short interest.


MRKR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to MRKR. When comparing the yearly performance of all stocks, MRKR is a bad performer in the overall market: 94.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MRKR Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to MRKR. The financial health of MRKR is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRKR Financial Highlights

Over the last trailing twelve months MRKR reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -28.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.73%
ROE -57.82%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-35.69%
Sales Q2Q%113.16%
EPS 1Y (TTM)-28.38%
Revenue 1Y (TTM)99.34%

MRKR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to MRKR. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -123.21% and a revenue growth -61.26% for MRKR


Ownership
Inst Owners41.79%
Ins Owners2.56%
Short Float %2.04%
Short Ratio1.51
Analysts
Analysts86
Price Target11.09 (809.02%)
EPS Next Y-123.21%
Revenue Next Year-61.26%